溶瘤病毒联合抗体阻断 TGF-β 增强靶向 αvβ6 的 CAR-T 细胞在免疫健全模型中抗胰腺癌的疗效

The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells Against Pancreatic Cancer in an

本研究提出了一种靶向 v 6 的鼠源 CAR-T 细胞，为开发实体瘤 CAR-T 细胞技术提供了新途径，并可能成为胰腺癌的潜在辅助治疗。

携带 IL-12 的溶瘤 HSV-2 增强 CAR-T 细胞在异种移植模型中对胰腺癌的疗效

IL-12-armed oncolytic HSV-2 enhances CAR T cell efficacy against pancreatic cancer in xenografted models.

这种协同策略以降低的 CAR-T 剂量实现了持久而强效的肿瘤清除，为胰腺癌及其他具有挑战性的实体恶性肿瘤提供了一种变革性策略。

KRAS 突变型胰腺癌免疫治疗的最新进展

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.

表达干扰素的溶瘤腺病毒联合放化疗在仓鼠模型中抑制了胰腺癌生长

Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model.

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

一种携带 CD47 纳米抗体的新型溶瘤痘病毒通过重塑免疫微环境治疗胰腺癌

A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment.

胰腺癌细胞免疫治疗的下一波浪潮

The next wave of cellular immunotherapies in pancreatic cancer.

溶瘤腺病毒联合 PD-L1 靶向放射免疫疗法对胰腺癌产生协同抗肿瘤效应

Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer.

我们的研究结果表明，HY-oAd 能以多方面的方式增强 177 Lu-aPD-L1 在肿瘤内的积聚，从而激发针对促结缔组织增生性和免疫原性差的胰腺肿瘤的协同抗肿瘤免疫反应。

溶瘤疱疹病毒增强 CAR 靶抗原表达对间皮素 CAR-T 细胞治疗胰腺癌的增效作用

Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression.

编码 4-1BBL 和 IL15 的溶瘤病毒增强肝细胞癌中 TIL（肿瘤浸润淋巴细胞）过继治疗的疗效

Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC.